Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease
© Connors et al.; licensee BioMed Central Ltd. 2014
Received: 22 April 2014
Accepted: 26 June 2014
Published: 14 July 2014
Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus-associated lymphoproliferative disorder. It most often occurs in patients with immunodeficiency and the clinical course ranges from indolent behavior to that of an aggressive malignancy. Pulmonary, central nervous system and dermatological manifestations are most common. To our knowledge this is the first reported case of LYG related to azathioprine therapy in Crohn disease.
A twenty-six year old Caucasian woman with colonic Crohn disease on maintenance azathioprine therapy presented with right upper quadrant pain and fever. Diagnostic imaging revealed extensive liver, pulmonary and cerebral lesions. A diagnosis of LYG was made based on the pattern of organ involvement and the immunohistochemical features on liver and lung biopsy.
Thiopurine therapy for inflammatory bowel disease is associated with an increased incidence of lymphoproliferative disorders. This report highlights the diagnostic challenges associated with LYG. As long-term thiopurine therapy remains central to the management of inflammatory bowel diseases it is essential that both patients and clinicians are aware of this potential adverse outcome.
KeywordsLymphoproliferative disorders Crohn disease Inflammatory bowel disease Azathioprine Thiopurines
Lymphomatoid granulomatosis (LYG), first described by Liebow et al. in 1972 , is a rare Epstein-Barr Virus (EBV)-associated lymphoproliferative disorder. LYG is classically described as primarily extranodal in nature involving the lungs, skin, central nervous system and liver. It is an incompletely understood clinical entity with a median survival of 14 months from the time of diagnosis. Age at first presentation is typically between the fourth and sixth decade with a male to female ratio of two to one. Although it may occur in immunocompetent hosts, there is a strong association with immune deficiency, both humoral and cell mediated. Clinical presentation is often non-specific with pulmonary involvement being most common and manifesting as cough, shortness of breath or chest pain [1–4].
Histopathologically, LYG is characterized as a mixed mononuclear cell infiltrate with atypical large CD20+ B-lymphocytes on the background of reactive CD3+ T- lymphocytes, histiocytes and plasma cells. The infiltrate is angiocentric and typically invades the microvasculature. It is graded from I to III based on both the number of large B-cells and the proportion that stain positively for EBV-encoded small RNA (EBER) by in situ hybridization (ISH) . The presence of these EBER-positive large B-cells and vascular invasion are keys to the diagnosis of LYG. Grade I and II LYG are slowly progressive while grade III LYG is aggressive with poor prognosis and requires treatment with multi-agent immunochemotherapy.
Here we present a case of LYG in a 26-year-old Caucasian female receiving azathioprine maintenance therapy for Crohn disease (CD) who presented with primary gastrointestinal complaints and fever. This report will highlight the diagnostic challenges associated with LYG and describe what we believe to be the first documented case of this rare disease in the setting of azathioprine treatment for CD.
A 26-year-old Caucasian woman presented with three days of right upper quadrant pain, fever, and malaise. She had a six-year history of Crohn colitis initially treated with high dose mesalamine (4 g daily) then transitioned to azathioprine (2.5 mg/kg) after loss of response. She had been in clinical remission on azathioprine for the preceding 14 months. The patient had not been on any other immune modulating or biologic therapies.
The patient opted to leave hospital pending consultation opinions on her liver biopsy and one month later returned to hospital with worsening dyspnea, cough and fevers. She underwent video-assisted thoracoscopic surgery (VATS) during which a wedge biopsy of her lung was obtained. In the days prior to surgery she had developed right pleural effusion and lower lobe pneumonia. Cultures from her pleural fluid grew Streptococcus milleri and Prevotella species, therefore she received a six-week course of parenteral antibiotics.Now four months after her initial presentation, the VATS-acquired lung wedge biopsy demonstrated EBER positivity in an atypical CD20+ lymphocyte infiltrate with vascular invasion sufficient to confirm a diagnosis of grade II LYG (Figure 2C, D). Expert pathology opinion from the National Institutes of Health (Bethesda, MD) concurred with the diagnosis. Over this period the patient had several transient episodes of left lower face and tongue paresthesias and repeat brain MRI revealed interval development of new enhancing lesions in both cerebral hemispheres with mild surrounding edema and small internal foci of microhemorrhage.
Treatment was initiated with subcutaneous recombinant interferon-alpha three times weekly titrated up to 10 million units per m2 of body surface area and four weekly doses of rituximab 375 mg/m2. Her treatment course was complicated by neutropenia requiring granulocyte colony stimulating factor (G-CSF), choledocholithiasis requiring cholecystectomy and admission to hospital with recurrent pneumonia. With therapy, all of her systemic lesions have steadily improved. This patient is alive and tolerating ongoing therapy at 12 months follow-up.
Our patient is the first reported case we are aware of with LYG in the context of CD and azathioprine use. Her presentation is atypical for LYG due to her young age, female gender, and the predominance of hepatic involvement preceding other pulmonary and CNS manifestations. In the larger context of LYG, only three percent of cases present with gastrointestinal symptoms; the majority primarily manifest pulmonary symptoms [1–4].
In our case, the diagnosis of LYG was suspected based on pattern recognition on lung imaging and suggestive liver pathology. The negative EBV staining and lack of necrosis on the liver biopsy sample pointed away from LYG as the diagnosis. After open lung biopsy, however, the classic features of LYG were revealed, namely atypical large B-cells that were EBER-positive, vascular invasion and necrosis. These pathological findings along with the patient’s clinical presentation and pattern of organ involvement clinched the diagnosis of LYG. This case highlights the difficulty of establishing the diagnosis of LYG in many cases due to sampling error and histological heterogeneity in a given patient depending on the site biopsied .
The current literature on LYG in association with CD or azathioprine is limited to two case reports. The first was a 17-year-old female patient with CD who developed LYG (stage III) with nasopharyngeal and pulmonary predominance following six years of 6-mercaptopurine therapy. She received systemic immunochemotherapy and was in clinical remission at four years follow-up . The second was a 69-year-old female who developed LYG (stage III) with central nervous system predominance following ten months of azathioprine therapy for autoimmune hepatitis. Despite initiation of systemic therapy the patient died 34 days after diagnosis due to sepsis and cardio-pulmonary failure . From these two case reports an independent association between the two major features of our case -CD and azathioprine (a thiopurine pro-drug of 6-mercaptopurine)– with the development of LYG can be theorized.
Multiple population-based studies of inflammatory bowel diseases (IBD) have not shown an excess risk of lymphoproliferative disorders (LD) over baseline in part because it is difficult to rule out an effect from the disease itself in the population of patients who require more intensive therapy [8, 9]. However, studies evaluating the risk of LD in the setting of CD and thiopurine therapy, summarized in a review by Beaugerie et al, support an approximate five-fold therapy specific elevated risk. Along with other smaller retrospective cohort analyses, the CESAME study, a nationwide French prospective observational cohort study of 19,486 patients with IBD, showed an independent association between ongoing thiopurine therapy for IBD and the risk of LD (multivariate-adjusted hazard ratio = 5.28, CI 2.01-13.9, p = 0.0007) [10–12]. It should be noted that the CESAME Study Group concluded the absolute cumulative risk of LD after ten years of thiopurines was less than one percent. This cohort had no patients diagnosed with LYG.
Consistent with the findings in our patient, a comprehensive review of all LYG case series by Katzenstein et al. illustrates the central role of underlying primary or secondary immunodeficiency leading to EBV reactivation. This may result in viral binding of lymphocyte membrane proteins and subsequent viral genome insertion facilitating oncogenesis . Iatrogenic T-cell immunosuppression secondary to thiopurines is consistent with this proposed pathogenesis and was likely the predisposing factor in our case. Crohn disease-related lymphomas have been shown to have a higher prevalence of EBV-related subtypes, and in some EBV-related lymphoproliferative disorders disease remission has been seen with withdrawal of immunosuppression .
Here we present the first case in the literature of lymphomatoid granulomatosis in the setting of azathioprine therapy for Crohn disease. LYG is one of several EBV-driven conditions that should be considered when a lymphoproliferative disorder develops in an immunocompromised patient.
The atypical features in our case underscore the importance of maintaining a high degree of clinical suspicion and diagnostic vigilance when evaluating non-specific abdominal symptoms frequently encountered in CD patients. This case highlights that even limited exposure to such therapy may induce LYG. Future research is needed into the pathogenesis and early detection of this disease to allow both clinicians and patients to make informed decisions and to raise awareness of this uncommon disorder.
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Central nervous system
Epstein-Barr virus encoded small RNA
Gamma glutamyl transferase
Inflammatory bowel disease
In situ hybridization
We thank Dr. J.H. MacGregor for assistance with case related diagnostic imaging and Dr. Michelle Geddes for clinical insight and expert opinion from a hematology-oncology perspective.
- Liebow AA, Carrington CR, Friedman PJ: Lymphomatoid granulomatosis. Hum Pathol. 1972, 3: 457-558. 10.1016/S0046-8177(72)80005-4.View ArticlePubMedGoogle Scholar
- Jaffe ES, Wilson WH: Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications. Cancer Surv. 1997, 30: 233-248.PubMedGoogle Scholar
- Fauci AS, Haynes BF, Costa J, Katz P, Wolff SM: Lymphomatoid granulomatosis. Prospective clinical and therapeutic experience over 10 years. N Engl J Med. 1982, 306: 68-74. 10.1056/NEJM198201143060203.View ArticlePubMedGoogle Scholar
- Katzenstein AL, Doxtader E, Narendra S: Lymphomatoid granulomatosis: insights gained over 4 decades. Am J Surg Pathol. 2010, 34: e35-e48. 10.1097/PAS.0b013e3181fd8781.View ArticlePubMedGoogle Scholar
- Colby TV: Current histological diagnosis of lymphomatoid granulomatosis. Mod Pathol. 2012, 25: S39-S42.View ArticlePubMedGoogle Scholar
- Destombe S, Bouron-DalSoglio D, Rougemont AL, Fournet JC, Ovetchkine P, Champagne J, Deslandres C: Lymphomatoid granulomatosis: a unique complication of Crohn disease and its treatment in pediatrics. J Pediatr Gastroenterol Nutr. 2010, 50: 559-561.PubMedGoogle Scholar
- Katherine Martin L, Porcu P, Baiocchi RA, Erter JW, Chaudhary AR: Primary central nervous system lymphomatoid granulomatosis in a patient receiving azathioprine therapy. Clin Adv Hematol Oncol. 2009, 7: 65-68.PubMedGoogle Scholar
- Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE: Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011, 106: 2146-2153. 10.1038/ajg.2011.283.View ArticlePubMedGoogle Scholar
- Lewis JD, Bilker WB, Brensinger C, Dern JJ, Vaughn DJ, Strom BL: Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001, 121: 1080-1087. 10.1053/gast.2001.28703.View ArticlePubMedGoogle Scholar
- Beaugerie L, Sokol H, Seksik P: Noncolorectal malignancies in inflammatory bowel disease: more than meets the eye. Dig Dis. 2009, 27: 375-381. 10.1159/000228577.View ArticlePubMedGoogle Scholar
- Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005, 54: 1121-1125. 10.1136/gut.2004.049460.View ArticlePubMedPubMed CentralGoogle Scholar
- Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, Cosnes J, Hebuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadie M, Hermine O, Faivre J, Carrat F, CESAME Study Group: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009, 374: 1617-1625. 10.1016/S0140-6736(09)61302-7.View ArticlePubMedGoogle Scholar
- Dayharsh GA, Loftus EV, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, Macon WR, Burgart LJ: Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002, 122: 72-77. 10.1053/gast.2002.30328.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/14/127/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.